Clinical Trial Update: A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety and effectiveness of cendakimab (CC-93538) in adults with moderate to severe atopic dermatitis has completed, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Cendakimab (cendakimab)

Snippet

Sponsor: Celgene | Conditions: Dermatitis, Atopic, Eczema | Phase 2 | Status: COMPLETED | Results posted: 2024-01-03